Browsing ICR Divisions by title
Now showing items 2117-2136 of 4580
-
Immune reconstitution in children following chemotherapy for acute leukemia.
(Wiley, 2020-07-01)Although survival rates for pediatric acute lymphoblastic leukemia are now excellent, this is at the expense of prolonged chemotherapy regimens. We report the long-term immune effects in children treated according to the ... -
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
(WILEY, 2023-06-01)Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome ... -
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors.
(NATURE PORTFOLIO, 2023-03-01)In cancer, evolutionary forces select for clones that evade the immune system. Here we analyzed >10,000 primary tumors and 356 immune-checkpoint-treated metastases using immune dN/dS, the ratio of nonsynonymous to synonymous ... -
Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.
(SPRINGERNATURE, 2020-10-13)BACKGROUND: Immunohistochemical quantification of the immune response is prognostic for colorectal cancer (CRC). Here, we evaluate the suitability of alternative immune classifiers on prognosis and assess whether they ... -
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.
(AMER ASSOC CANCER RESEARCH, 2020-01-01)Before squamous cell lung cancer develops, precancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. Although ... -
Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.
(MDPI, 2020-12-29)Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus resulting in high morbidity and mortality. Among all cancers, with a five-year survival rates of only 2-9%, pancreatic cancer ... -
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.
(2018-01)Immune-checkpoint inhibitors (ICPIs), including antibodies against cytotoxic T-lymphocyte associated antigen 4 and programmed cell death protein 1, have been shown to induce durable complete responses in a proportion of ... -
Immuno-oncology combinations: raising the tail of the survival curve.
(2016-06)There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small ... -
Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma.
(MDPI, 2023-06-09)There is no established method to assess the PD-L1 expression in brain tumours. Therefore, we investigated the suitability of affibody molecule (ZPD-L1) radiolabelled with F-18 (Al18F) and Ga-68 to measure the expression ... -
Immuno-PET in Pontine Glioma: More Than Meets the Eye?
(SOC NUCLEAR MEDICINE INC, 2018-04-01) -
Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.
(WILEY, 2017-08-01)Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies; however, the presence of resistant mutations necessitates both the development of more ... -
Immunogenic cell death in cancer therapy
(Institute of Cancer Research (University Of London), 2024-01-16)Triple negative breast cancer (TNBC) is a heterogenous disease which carries a poor prognosis, with the worst outcomes in the basal-like subtype. Despite the introduction of immunotherapy in the treatment paradigm the ... -
Immunogenicity of self tumor associated proteins is enhanced through protein truncation.
(CELL PRESS, 2016-12-07)We showed previously that therapy with Vesicular Stomatitis Virus (VSV) expressing tumor-associated proteins eradicates established tumors. We show here that when cellular cDNA were cloned into VSV which retained their own ... -
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
(AMER SOC CLINICAL INVESTIGATION INC, 2018-10-01)BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss ... -
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
(2017-03)The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (<i>n</i> = 2,471) were randomly assigned to ... -
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients.
(2022-03-02)Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis and few available systemic treatment options. Trabectedin is currently being investigated as a potential adjunct to immunotherapy as it has been ... -
Immunological combination treatment holds the key to improving survival in pancreatic cancer.
(2020-11)Advances in surgery, peri-operative care and systemic chemotherapy have not significantly improved the prognosis of pancreatic cancer for several decades. Early clinical trials of immunotherapy have yielded disappointing ... -
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.
(NATURE PORTFOLIO, 2020-02-01)Therapeutic irradiation of the tumor microenvironment causes differential activation of pro-survival and pro-death pathways in malignant, stromal, endothelial and immune cells, hence causing a profound cellular and biological ... -
Immunomodulatory activity of IR700-labelled affibody targeting HER2.
(SPRINGERNATURE, 2020-10-20)There is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological responses by releasing ... -
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
(WILEY, 2014-03-01)Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) . T cell co-stimulation by lenalidomide or pomalidomide is cereblon ...